‘CARTISTEM’ shows superb results from 3 year long term tracking clinical trials

Core dementia treatment technology patented at 6 European countries, concurrently

MEDIPOST, achieves ‘150 patent applications and 50 patent registrations’

US ‘Stem cells regenerative medicine congress’ invites MEDIPOST for the first time as a Korean company

MEDIPOST announced extension plans in US ’2015 Stem Cell Meeting on the Mesa’

Selected as a conducting company of ‘global high-tech biomedicine industry’

‘PNEUMOSTEM’ selected as the ‘Newly developed and promising medical technology’ by National evidence based healthcare collaborating agency

What is “CARTISTEM” used for treatment of Hiddink?

Singapore/Taiwan consecutively invited MEDIPOST to its stem cell forums

MEDIPOST Obtains Stem Cell Therapy Patent in Japan for Treating Alzheimer’s Disease

MEDIPOST Obtains Patent in Canada for its ‘PNEUMOSTEM’ Used to Treat Lung Diseases

MEDIPOST Obtains Patent in China for its Alzheimer’s Disease Treatment Substance